KaliVir doses first subject in Phase I/Ib solid tumour treatment trial [Yahoo! Finance]
ASTELLAS PHARMA UNSP/ADR (ALPMY)
NASDAQ:AMEX Investor Relations:
astellas.com/jp/en/investors
Company Research
Source: Yahoo! Finance
Patients will receive the treatment either by direct tumour injection or intravenous infusion. The dose escalation portion aims to establish the highest tolerated dose of VET3-TGI across different methods of administration, including when combined with checkpoint blockade therapy. Following the determination of the maximum tolerated dose for each administration group, the trial will proceed to expansion cohorts, which are designed to further investigate the safety profile and therapeutic effectiveness of VET3-TGI. The study is currently enrolling subjects who have pathologically confirmed advanced, unresectable, or metastatic solid tumours. KaliVir focuses on developing next-generation oncolytic immunotherapies. The company leverages the capabilities of the vaccinia platform to engineer viral backbones that enhance the delivery and targeted expression of therapeutic transgenes within tumours. Its vaccinia-enhanced template (VET) platform is instrumental in the systemic de
Show less
Read more
Impact Snapshot
Event Time:
ALPMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALPMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALPMY alerts
High impacting ASTELLAS PHARMA UNSP/ADR news events
Weekly update
A roundup of the hottest topics
ALPMY
News
- Optical Imaging Agent Market Expected to Expand at 8.1% CAGR, Reaching US$ 3,533.2 Million by 2034 | Fact.MR Report [Yahoo! Finance]Yahoo! Finance
- Astellas Announces Desert Oasis Healthcare as First Health System to Implement DIGITIVA™ for Heart Failure Management [Yahoo! Finance]Yahoo! Finance
- Astellas Announces Desert Oasis Healthcare as First Health System to Implement DIGITIVA™ for Heart Failure ManagementPR Newswire
- KaliVir Immunotherapeutics Strengthens Innovation Portfolio with Issuance of Three New U.S. Patents Covering Its VET™ Product Candidates [Yahoo! Finance]Yahoo! Finance
- Should Value Investors Buy Astellas Pharma (ALPMY) Stock? [Yahoo! Finance]Yahoo! Finance